ECHODYNE
15.4.2024 09:01:30 CEST | Business Wire | Press release
Echodyne, the radar platform company, is excited to announce it will be addressing the second annual Counter UAS Technology Europe 2024 conference, taking place at the Marriott Hotel Grosvenor Square in London over April 16-17, 2024. Echodyne VP of Marketing, Leo McCloskey, will discuss important counter-UAS developments in accuracy and mobility. Echodyne’s participation in this year’s event comes on the heels of significantly expanding its footprint in the region with new, European-based team members.
The conference is hosted by SAE Media Group and focuses on gathering European C-UAS stakeholders to address the growing proliferation of small drones and unmanned aircraft system (UAS) technology and the need for European armed forces and security agencies to protect critical national infrastructure and personnel at home and abroad by way of cutting-edge, C-UAS operations.
Drones are an increasing threat beyond the battlefield with payload and operational capabilities that challenge existing sensors and systems. From low, slow, and very effective small UAS to larger Group 3 UAS, the threat to logistics, missions, and warfighters is vast and expanding. Part of the challenge is sensors that can accurately track and deliver precise airspace coordinates of the intruding UAS, for which Echodyne’s metamaterials electronically scanned array (MESA®) are uniquely capable.
Cost symmetry is another challenge, with non-state actors spending small amounts on UAS weapons that require multi-million dollar systems to defeat. Echodyne’s radars achieve the optimal balance of low-cost, commercial off-the-shelf (COTS) advanced technology and high-performance, active beamforming ESA precision to create the most powerful, low-SWaP radars on the market. With both processed and unprocessed data integration options, Echodyne radars generate the most accurate data for detecting, tracking, targeting, and mitigating UAS threats.
“Solving the ‘drone problem’ requires technology and software that, when integrated, contributes high-fidelity, actionable data from attritable COTS platforms,” said Todd Fraser, Chief Revenue Officer at Echodyne. “Customer requirements are rapidly and radically changing, from fixed and portable to highly mobile, from crewed to uncrewed to platforms, from range as the sole driver to greater emphasis on spatial accuracy. Echodyne is expanding to meet increasing customer demand across Europe, Middle East, and Africa for low SWaP, commercially-exportable radars with superior ESA performance.”
Those interested in learning more about Echodyne’s radar for C-UAS operations, including remote weapons stations (RWS), short-range air defense (SHORAD) programs, and more are invited to attend Echodyne’s session at the Counter UAS Technology Europe 2024 Conference at 11 am BST on April 16, 2024. Those who are unable to attend can connect directly with a member of the Echodyne team here.
About Echodyne
Echodyne, the radar platform company, is a U.S. designer and manufacturer of advanced radar solutions for defense, government, and commercial market applications. The company’s proprietary metamaterials electronically scanned array (MESA®) architecture is a rare breakthrough in advanced radar engineering. Echodyne’s innovative MESA radars use standard materials and manufacturing processes to shatter unit cost barriers for high performance radar. The result is a solid-state, low-SWaP, exportable, commercial radar with advanced software capabilities that delivers superior performance, unparalleled data integrity, and exceptional situational awareness. Privately held, the company is backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, Northrop Grumman, and Supernal, among others. For more information, please visit: Echodyne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415117922/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
